# AF on Dialysis: Exposure Is Not Proof of Benefit

Hospitalization, procedures, bleeding, changes in function, and new evidence can alter the balance. A previous decision does not remove the need for review.

![Infographic: AF on Dialysis: Exposure Is Not Proof of Benefit](https://urinenephrology.org/visual-reference/images/mastery-hd-anticoagulation.png?v=20261003c)

## A difficult risk balance

Dialysis patients can face both stroke and substantial bleeding risk. General-population risk scores and trials do not automatically transfer to this setting.

## Define the indication

Atrial fibrillation, venous thrombosis, valve disease, and access-related anticoagulation are different questions with different evidence.

## Separate pharmacology from outcomes

A drug concentration or anti-Xa effect demonstrates exposure, not proven stroke prevention or net clinical benefit for a particular dialysis dose.

## Share the decision

Discuss uncertain benefit, bleeding history, interactions, frailty, patient priorities, and alternatives. Dose selection must follow the indication and current prescribing framework.

## Chair-side observations

Report prolonged access bleeding, bruising, falls, melena, new neurologic symptoms, and medication changes. Verify rather than independently change the anticoagulant plan.

## Reassess repeatedly

Hospitalization, procedures, bleeding, changes in function, and new evidence can alter the balance. A previous decision does not remove the need for review.

## Source lessons

- [apixaban dose dialysis](https://urinenephrology.org/mastery/maintenance-hd/apixaban-dose-dialysis.html)
- [atrial fibrillation anticoagulation hd](https://urinenephrology.org/mastery/maintenance-hd/atrial-fibrillation-anticoagulation-hd.html)

Read alongside the full lessons; the findings and decisions shown here require the stated clinical context.